What is Moderna Inc (MRNA) stock price today?

Moderna Inc (MRNA) currently trades at $45.72 per share. The stock has a market capitalization of $18.13B and a P/E ratio of —x.

Is MRNA stock a buy, sell, or hold in 2026?

Based on WallStSmart's proprietary analysis, Moderna Inc has a Smart Value Score of 24/100 (Grade F), resulting in a "Strong Sell" investment rating. The Piotroski F-Score is 3/9 and Altman Z-Score is 3.00.

What is Moderna Inc's revenue and earnings?

Moderna Inc has trailing twelve-month (TTM) revenue of $1.94B with profit margins of -145.20%. Earnings per share (EPS) is $-7.26.

Is Moderna Inc financially healthy?

Moderna Inc's Piotroski F-Score is 3/9 (weak financial health). The Altman Z-Score of 3.00 places it in the safe zone.

Is MRNA stock overvalued or undervalued?

Based on our DCF model, Moderna Inc's intrinsic value is $133.04, representing a margin of safety of 69.55%. The stock currently trades at a P/E of —x.

MRNA

Moderna Inc

NASDAQ: MRNA · HEALTHCARE · BIOTECHNOLOGY

$45.72

-3.01% today

Updated 2026-04-29

Market cap

$18.13B

P/E ratio

—

P/S ratio

9.33x

EPS (TTM)

$-7.26

Dividend yield

—

52W range

$22 – $60

Volume

7.5M

Market cap

$18.13B

P/E ratio

—

P/S ratio

9.33x

EPS (TTM)

$-7.26

Dividend yield

—

52W range

$22 – $60

Volume

7.5M

WallStSmart proprietary scores

out of 100

Grade: F

Strong Sell

Investment rating

2.0

Growth

7.3

Quality

B+

2.0

Profitability

6.7

Valuation

3/9

Piotroski F-Score

Weak

3.0

Altman Z-Score

Safe zone

—

Industry rank

—

View all highly rated stocks (75+) →202 stocks currently score above 75

Price targets

Analyst target

$41.42

-9.41%

12-Month target

—

Intrinsic (DCF)

$133.04

Margin of safety

+69.55%

2 Strong Buy2 Buy17 Hold1 Sell2 Strong Sell

Price chart

X-Ray snapshot

Strengths

+ Altman Z 3.00 — safe zone

+ Free cash flow $912.00M — positive

+ 69.55% below intrinsic value

Risks

- Piotroski 3/9 — weak financial health

- Thin margins at -145.20%

- Revenue declining -29.80% QoQ

Key financials

Revenue Net Income Free Cash Flow

Metric	2022	2023	2024	2025	TTM	2026 (E)
Revenue	$18.88B	$6.85B	$3.20B	$1.94B	$1.94B	$2.1B
Net income	$8.36B	$-4.71B	$-3.56B	$-2.82B	$-826.00M	—
EPS	—	—	—	—	$-7.26	$-6.81
Free cash flow	$4.58B	$-3.83B	$-4.05B	$-2.06B	$912.00M	—
Profit margin	44.30%	-68.84%	-111.32%	-145.16%	-145.20%	—

Recent insider activity

Date	Insider	Type	Shares	Price
2026-04-02	MOCK, JAMES M	Sale	1,453	—
2026-04-02	MOCK, JAMES M	Buy	1,453	—
2026-04-02	MOCK, JAMES M	Sale	703	$50.03

Peer comparison

Company	Mkt Cap	Score	Growth	Profit	Value	Quality	MoS	Rating
MRNA	$18.13B	24	2.0	2.0	6.7	7.3	+69.55%	Avoid
LLY	$760.43B	78	10.0	10.0	5.0	6.5	—	Strong Buy
JNJ	$547.28B	59	4.7	9.0	3.3	6.0	-43.54%	Buy
ABBV	$360.63B	63	4.0	8.0	4.7	5.0	-29.31%	Buy
UNH	$322.34B	54	5.3	5.5	7.3	4.8	+42.06%	Buy
AZN	$294.17B	64	6.7	8.0	5.3	5.0	+4.07%	Buy

Smart narrative

Moderna Inc trades at $45.72. Our Smart Value Score of 24/100 indicates the stock is weak. The company scores 3/9 on the Piotroski F-Score. With an Altman Z-Score of 3.00, it sits in the safe zone. TTM revenue stands at $1.94B. with profit margins at -145.20%. Our DCF model estimates intrinsic value at $133.04.

Frequently asked questions

What is Moderna Inc's stock price?

Moderna Inc (MRNA) trades at $45.72.

Is Moderna Inc overvalued?

Smart Value Score 24/100 (Grade F, Strong Sell). DCF value $133.04.

What is the price target of Moderna Inc (MRNA)?

The analyst target price is $41.42, representing -9.4% downside from the current price of $45.72.

What is the intrinsic value of Moderna Inc (MRNA)?

Based on our DCF model, intrinsic value is $133.04, a +69.5% margin of safety versus $45.72.

What is the future stock price of MRNA by 2030?

Our research-backed model estimates Moderna Inc could reach $160.94 by 2030, based on analyst consensus, management guidance, and sector analysis.

What is Moderna Inc's revenue?

TTM revenue is $1.94B.

Piotroski F-Score?

3/9 — weak financial health.

Altman Z-Score?

3.00 — safe zone.

Company info

SectorHEALTHCARE

IndustryBIOTECHNOLOGY

CountryUSA

ExchangeNASDAQ

CurrencyUSD

Quick metrics

P/S ratio9.33x

ROE-28.90%

Beta1.34

50D MA$51.86

200D MA$35.56

Shares out0.40B

Float0.37B

Short ratio—

Avg volume7.5M

Performance

1 week-9.88%

1 month-8.61%

3 months+3.74%

YTD+55.04%

1 year—

3 years—

5 years—

Compare

MRNA vs LLY →MRNA vs JNJ →MRNA vs ABBV →Stock screener →